Generics & Biosimilars | Association for Accessible Medicines
GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!
  • Access Denied: Why New Generics Are Not Reaching America's Seniors
    New White Paper: Access Denied
    AAM's "Access Denied" white paper highlights new data on the treatment of generic medicines in Medicare Part D, resulting in patients paying more for their medicines even when lower-priced FDA-approved generics and biosimilars are available.
  • 2019 AAM Access & Savings report - pills image
    AAM's 2019 Access & Savings in the U.S. Report
    The quality and affordability of generic medicines makes possible greater access, adherence and improved health for millions of patients across the United States.
  • ""
    More Speakers + Opportunities
    It's shaping up to be the best lineup ever at GRx+Biosims 2019 with more than 40 influential speakers you don’t want to miss.
  • ""
    How Much Did Your State Save?
    Take a deeper look at state-by-state generic drug savings from the 2019 Generic Drug and Biosimilars Access & Savings in the U.S. report.
  • NAFTA 2.0: Obstacles to More Affordable Medicines for Americans
    NAFTA 2.0: Obstacles to More Affordable Medicines
    The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.